Pyelonephritis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Pyelonephritis Pipeline Insight, 2023” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Pyelonephritis pipeline landscape. It covers the Pyelonephritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pyelonephritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Pyelonephritis Pipeline Report
- DelveInsight’s Pyelonephritis pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Pyelonephritis treatment.
- The leading companies working in the Pyelonephritis Market include Wockhardt, Sinovent, Entasis Therapeutics, Melinta Therapeutics, and others.
- Promising Pyelonephritis Pipeline Therapies in the various stages of development include doripenem, Cefepime-zidebactam (FEP-ZID), Meropenem, levofloxacin, and others.
- October 2023: Meiji Seika Pharma Co. Ltd announced a study of Phase 3 clinical trials for BAT. This study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the treatment of patients with cUTI, AP, HABP, VABP, and cIAI, due to Carbapenem Resistant Enterobacterales.
- August 2023: Pfizer announced a study of Phase 4 clinical trials for Zavicefta, Ceftazidime-Avibactam. This is an open-label, randomized, multi-center, interventional, active-controlled Phase 4 study to evaluate the efficacy and safety of CAZ-AVI versus BAT in the treatment of infected participants with selected infection types (Hospital Acquired Pneumonia [HAP] (including Ventilator-Associated Pneumonia [VAP]); Complicated Urinary-Tract Infection [cUTI]; Complicated Intra-Abdominal Infection [cIAI]; Bloodstream Infection [BSI]) due to carbapenem-resistant Gram-negative pathogens in China.This study will be an estimation study. The statistical inference will be based on point estimate and confidence interval.
- July 2023: Hamad Medical Corporation announced a study of Phase 3 clinical trials for Dexamethasone Oral. Urinary tract infection (UTI) is the most frequently occurring serious bacterial infection in young children and accounts 5 to 14% of emergency department visits Formation of renal scarring in children has been associated with serious complications as hypertension, preeclampsia, and end stage renal failure in young age. So, this study aims to determine whether dexamethasone reduces the renal scarring in children will be treated with antibiotics for acute pyelonephritis.
Request a sample and discover the recent advances in Pyelonephritis Treatment Drugs @ Pyelonephritis Pipeline Report
In the Pyelonephritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pyelonephritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pyelonephritis Overview
Pyelonephritis is a type of urinary tract infection where one or both kidneys become infected. They can be infected by bacteria or a virus. It can cause people to feel very sick and it requires treatment. There are approximately 250,000 cases of acute pyelonephritis each year, resulting in more than 100,000 hospitalizations.
Find out more about Pyelonephritis Therapeutics Assessment @ Pyelonephritis Preclinical and Discovery Stage Products
Pyelonephritis Emerging Drugs Profile
- WCK-5222: Wockhardt
- XNW 4107: Sinovent
- ETX2514SUL: Entasis Therapeutics
Pyelonephritis Pipeline Therapeutics Assessment
There are approx. 8+ key companies which are developing the Pyelonephritis therapies. The Pyelonephritis companies which have their Pyelonephritis drug candidates in the most advanced stage, i.e. Phase III, Wockhardt.
DelveInsight’s Pyelonephritis pipeline report covers around 8+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Pyelonephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Pyelonephritis Pipeline Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Learn more about the emerging Pyelonephritis Pipeline Therapies @ Pyelonephritis Clinical Trials Assessment
Scope of the Pyelonephritis Pipeline Report
- Coverage- Global
- Pyelonephritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Pyelonephritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Pyelonephritis Companies- Wockhardt, Sinovent, Entasis Therapeutics, Melinta Therapeutics, and others.
- Pyelonephritis Pipeline Therapies- doripenem, Cefepime-zidebactam (FEP-ZID), Meropenem, levofloxacin, and others.
Dive deep into rich insights for new drugs for Pyelonephritis Treatment, Visit @ Pyelonephritis Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Pyelonephritis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Pyelonephritis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- WCK-5222: Wockhardt
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- ETX2514SUL: Entasis Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Pyelonephritis Key Companies
- Pyelonephritis Key Products
- Pyelonephritis- Unmet Needs
- Pyelonephritis- Market Drivers and Barriers
- Pyelonephritis- Future Perspectives and Conclusion
- Pyelonephritis Analyst Views
- Pyelonephritis Key Companies
- Appendix
For further information on the Pyelonephritis Pipeline therapeutics, reach out to Pyelonephritis Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pyelonephritis-market
